Pharmaceutical Dermatology · Prescribed by 2,500+ Dermatologists
HomeTherapeutic PortfoliosAntifungal & Psoriasis Care
Superficial Mycoses, Tinea & Hyperkeratotic Plaques

Antifungal & Psoriasis Care

Relief Today. Healthier Tomorrow.

Broad-spectrum antifungal agents and keratolytic corticosteroid combinations designed for rapid relief from fungal infections and stubborn psoriatic plaques.

Formulations in Clinical Development · Coming Soon
Pharmacology & Mechanism
Antifungal & Psoriasis Care
Key Bioactive Complex

Eberconazole 1% · Ketoconazole 2% · Luliconazole 1% · Clobetasol + Salicylic Acid

Prescription & OTC Portfolio

Formulations in Antifungal & Psoriasis Care

Each product is manufactured in compliance with international cGMP standards and verified by HPLC assay.

Formulations in Clinical Research & Regulatory Submission

DermaGenesis has therapeutic dossiers currently under active phase trial and stability testing in this discipline. Registered dermatologists can contact Medical Affairs for pipeline monograph access.

Cellular Pharmacology

Dual Mechanism Fungal Clearance & Scale Reduction

High-affinity ergosterol biosynthesis inhibition disrupts fungal cell membranes, while synergistic keratolytic action breaks down hyperkeratotic plaque scale.

Pathological Target Indications

1

Tinea Cruris & Corporis

Rapid mycological clearance and pruritus suppression within 72 hours.

2

Chronic Plaque Psoriasis

Thins hyperkeratotic plaques and eliminates silvery scaling.

3

Seborrheic Dermatitis

Controls Malassezia fungal overgrowth on scalp and facial folds.

4

Cutaneous Candidiasis

Clears fungal colonization in intertriginous areas.

Clinical Administration Protocols

✓

Application Margin

Apply a thin layer covering the lesion and 1 inch of healthy perimeter.

✓

Course Completion

Continue therapy for direct prescribed duration to prevent recurrence.

✓

Hygiene Practices

Keep affected areas clean and completely dry before application.

Clinical Inquiries

Frequently Asked Questions